Why Is ZBH Stock Dropping Today? Zimmer Biomet Falls After Restructuring Announcement

Zimmer Biomet (ZBH) shares fell 5.88% in pre-market trading after the company announced a restructuring plan that includes proposed job cuts at a Swiss manufacturing plant and the departure of a group president.

The simultaneous announcements signal a continued overhaul at the orthopedic device maker, as CEO Ivan Tornos reshapes both the company's manufacturing footprint and its Americas leadership structure.

What Did Zimmer Biomet Announce?

Zimmer Biomet proposed cutting 580 jobs at its Winterthur, Switzerland manufacturing plant, the company said in a news release. The cuts would represent 3.4% of the roughly 17,000 positions listed in its most recent annual report. The company has not made a final decision and has begun a works council collective consultation to evaluate alternatives and limit job losses. The move falls under what Zimmer Biomet calls its "manufacturing network optimization strategy," aimed at simplifying its global supply chain and improving long-term efficiency.

At the same time, the company is restructuring its Americas and Global Business Group leadership. Group President Kevin Thornal is departing effective September 30, 2026. According to an SEC filing, Thornal's position was restructured — he did not resign voluntarily. He is eligible for severance under the company's executive plan, including 12 months of base salary, a target annual bonus, and 12 months of COBRA premiums.

Three internal executives are set to fill the void starting October 1. Gary Campbell will become President, Americas; Brian Hatcher will take over Recon, S.E.T., CMFT, Neuro and Biosurgery; and Bradley Kessler will lead Americas – Robotics, Technology and Data. All three will report directly to Tornos.

Why Does The Restructuring Matter?

For investors, the layered changes raise both strategic and execution questions. The Winterthur plant has a long manufacturing heritage in Switzerland, and trimming 580 roles suggests the company is willing to consolidate even well-established operations in pursuit of supply chain efficiency. That said, the cuts remain proposed, and the works council process could alter the final scope.

The Thornal departure is the sharper signal. He joined Zimmer Biomet last year after leading Nevro through its $250 million sale to Globus Medical — a hire that pointed to Tornos's ambition to accelerate the company's commercial transformation. The fact that his position was restructured rather than a voluntary exit suggests the organizational design has not played out as expected. The three promotions that replace his role split his responsibilities across multiple leaders, which could create decision-making friction during the transition.

What Should Investors Watch Next?

The works council consultation in Switzerland determines whether the 580 proposed cuts move forward, get modified, or are withdrawn entirely. European works council processes typically run for weeks, so the outcome is not immediate.

On the leadership side, investors will watch how Campbell, Hatcher, and Kessler handle the overlapping portfolios in their first months. Tornos has framed the promotions as a way to sharpen ownership and accelerate the company's U.S. go-to-market transformation.

Pre-market liquidity is often thinner than regular-session volume, so the full extent of the reaction may not be clear until the opening bell. With the Winterthur restructuring still only proposed and a new leadership structure taking shape in October, investors have reason to watch both the trading session and the company's follow-up disclosures.